Leukemia
Conditions
Keywords
Leukemia, Myelodysplastic Syndrome, MDS, Omacetaxine, Synribo, Homoharringtonine
Brief summary
The goal of this clinical research study is learn if omacetaxine can help to control myelodysplastic syndrome (MDS). The safety of this drug will also be studied. This is an investigational study. Omacetaxine is FDA approved and commercially available for the treatment of chronic myelogenous leukemia (CML). It is investigational to use omacetaxine in patients with MDS. The study doctor can explain how the study drug is designed to work. Up to 80 participants will be enrolled in this study. All will take part at MD Anderson.
Detailed description
Study Drug Administration: Each cycle will be 4-7 weeks, depending on how well the disease responds to the study drug. If you are found to be eligible to take part in this study, you will receive omacetaxine as an injection under your skin 2 times each day, about 12 hours apart, on Days 1-3 of every 28-day study cycle. You will receive instructions on how to give these injections to yourself. You will be given a Research Drug Diary to record the drug you take each day. You must bring the Research Drug Diary and any unused drug with you to each study visit. You will also be told how to properly store the drugs. Depending on how the disease responds to the study drugs, the number of days you receive your injections may stay the same, increase, or decrease. Your doctor will discuss this with you. During Cycle 1, if the doctor thinks it is needed, you will be given hydroxyurea by mouth to decrease the risk of side effects. You may ask the study staff for information about how the drug is given and its risks. Study Visits: At the beginning of every cycle, you will have a physical exam before your dose of study drug. Every week (+/- 2 days), blood (about 2-3 teaspoons) will be drawn for routine tests. If the disease appears to get better, this blood will only be drawn every 2-4 weeks while you are still receiving the study drugs. If you live far from the clinic, this blood can be drawn at a clinic close to your home, and the results will be reported to the study doctor. If the study doctor thinks it is needed, you may have an additional bone marrow aspirate at any time during the study to check the status of the disease and for cytogenetic testing. Length of Study: You may continue taking the study drug for up to 24 cycles of treatment. You will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions. Your participation on the study will be over after the follow-up visits. Follow-Up: You will have follow-up visits at the clinic every 3-6 months for up to 5 years after you stop taking the study drug. You will be asked about your health and any new drugs you may be taking. If you cannot come to the clinic, you will be called by the study staff and asked about your health. These calls should last about 5-10 minutes. Every 4-8 weeks after your last dose of study drug, blood (about 2-3 teaspoons) will be drawn for routine tests.
Interventions
DRUGOmacetaxine
1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
Sponsors
Teva Pharmaceuticals USA
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age \>/= 18 years 2. Diagnosis of MDS confirmed within 10 weeks prior to study entry according to WHO criteria. Patients are either not eligible for or choose not to proceed with a stem cell transplant. 3. MDS classified as follows: RAEB-1 (5%-9% BM blasts); RAEB-2 (10%-19% BM Blasts); CMML (5%-19% BM blasts); RAEB-t (20%-29% BM blasts) AND/OR by IPSS: intermediate-1 and high risk patients. 4. No response, progression, or relapse (according to 2006 IWG criteria) following at least 4 cycles of either azacitidine or decitabine, which were completed within the last 2 years - AND/OR - intolerance to azacitidine or decitabine defined as drug-related \>/= grade 3 hepatic or renal toxicity leading to treatment discontinuation during the preceding 2 years. 5. Eastern Cooperative Oncology Group (ECOG) performance status of \</= 2. 6. Willing to adhere to and comply with all prohibitions and restrictions specified in the protocol. 7. Patient (or patient's legally authorized representative) must have signed an informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study.)
Exclusion criteria
1. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia. 2. Active infection not adequately responding to appropriate antibiotics (i.e. ongoing temperatures of \>/= 38 degree Celsius). 3. Total bilirubin \>/= 1.5 mg/dL and not related to hemolysis or Gilbert's disease. Patients with total bilirubin \>/= 1.5 mg/dL to 3 mg/dL are eligible if at least 75% of the bilirubin is indirect. 4. Alanine transaminase (ALT/SGPT) or aspartate transaminase (AST/SGOT) \>/= 2.5 x the upper limit of normal. 5. Serum creatinine \> 1.5 mg/dL. 6. Female patients who are pregnant or lactating. 7. Patients with reproductive potential who are unwilling to following contraception requirements (including condom use for males with sexual partners, and for females: prescription oral contraceptives \[birth control pills\], contraceptive injections, intrauterine devices \[IUD\], double-barrier method \[spermicidal jelly or foam with condoms or diaphragm\], contraceptive patch, or surgical sterilization) throughout the study. 8. Female patients with reproductive potential who do not have a negative urine or blood beta-human chorionic gonadotropin (beta HCG) pregnancy test at screening. 9. Patients receiving any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy. 10. Prior hydroxyurea for control of leukocytosis or use of hematopoietic growth factors (eg, G-CSF, GM-CSF, procrit, aranesp, thrombopoietins) is allowed at any time prior to or during study if considered to be in the best interest of the patient. 11. Psychiatric illness or social situation that would limit the patient's ability to comply with study requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 2.5 Years | Overall survival defined as the time from treatment start to the time of death. Overall survival continuously monitored using the Bayesian method. |
| Number of Participants With a Response | Up to 2 years | Response is Complete Response (CR) + Partial Response (PR) + Hematologic Improvement (HI). CR is the normalization of the peripheral blood and bone marrow with \</= 5% bone marrow blasts, a peripheral blood granulocyte count \>/= (1.0x10\^9/L, and a platelet count \>/= 100x10\^9/L). PR is the same as CR except for the presence of 6-15% marrow blasts, or 50% reduction if \<15% at start of treatment. HI meets all of the criteria for CR except for platelet recovery to \>/=100x10\^9L. |
Countries
United States
Participant flow
Recruitment details
Recruitment Period: May 2015 to September 2018
Participants by arm
| Arm | Count |
|---|---|
| Omacetaxine Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.
Omacetaxine: 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. | 48 |
| Total | 48 |
Baseline characteristics
| Characteristic | Omacetaxine |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 43 Participants |
| Age, Categorical Between 18 and 65 years | 5 Participants |
| Age, Continuous | 75.5 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 42 Participants |
| Region of Enrollment United States | 48 participants |
| Sex: Female, Male Female | 17 Participants |
| Sex: Female, Male Male | 31 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 15 / 48 |
| other Total, other adverse events | 23 / 48 |
| serious Total, serious adverse events | 30 / 48 |
Outcome results
Primary
Number of Participants With a Response
Response is Complete Response (CR) + Partial Response (PR) + Hematologic Improvement (HI). CR is the normalization of the peripheral blood and bone marrow with \</= 5% bone marrow blasts, a peripheral blood granulocyte count \>/= (1.0x10\^9/L, and a platelet count \>/= 100x10\^9/L). PR is the same as CR except for the presence of 6-15% marrow blasts, or 50% reduction if \<15% at start of treatment. HI meets all of the criteria for CR except for platelet recovery to \>/=100x10\^9L.
Time frame: Up to 2 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Omacetaxine | Number of Participants With a Response | 16 Participants |
Primary
Overall Survival (OS)
Overall survival defined as the time from treatment start to the time of death. Overall survival continuously monitored using the Bayesian method.
Time frame: Up to 2.5 Years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Omacetaxine | Overall Survival (OS) | 7.5 Months |